Recent Updates
Recently added Catalysts
SLBT Positive Sentiment

SL Science Holding Limited Completes Business Combination and Lists on the Nasdaq Global Market (Formerly known as SL BIO Ltd.)

Sunday, June 14, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: SL Science Holding Limited, previously known as SL BIO Ltd., has successfully completed its business combination and is now trading on the Nasdaq Global Market as SLBT. The company focuses on developing allogeneic GDT cell-based therapies aimed at treating pancreatic cancer and glioblastoma. This advancement marks a significant step in their therapeutic offerings.

Market Sentiment Analysis

POSITIVE FACTORS

  • Company completed a successful business combination.
  • SLBT is now listed on the Nasdaq Global Market.
  • Advancing innovative therapies for pancreatic cancer and glioblastoma.

Full Press Release Details

Formerly known as SL BIO Ltd., SL Science Holding Limited (Nasdaq: SLBT) began trading on the Nasdaq Global Market on June 15, 2026. The company is advancing allogeneic GDT cell-based off-the-shelf therapies targeting pancreatic cancer and glioblastoma. Read more.

Frequently Asked Questions

What is SL Science Holding Limited's new ticker symbol?

The new ticker symbol for SL Science Holding Limited is SLBT.

When did SLBT start trading on Nasdaq?

SLBT began trading on the Nasdaq Global Market on June 15, 2026.

What types of therapies is SLBT developing?

SLBT is advancing allogeneic GDT cell-based therapies targeting pancreatic cancer and glioblastoma.

What was SLBT previously known as?

SLBT was formerly known as SL BIO Ltd.

ShareAdd on Google
Tags: SLBT Viatris Investor Conferences Healthcare Nasdaq pancreatic cancer glioblastoma cell-based therapies
Last updated: Jun 14, 2026